Matching articles for "acetylsalicylic acid"
Vazalore - A New Aspirin Formulation
The Medical Letter on Drugs and Therapeutics • May 2, 2022; (Issue 1649)
The FDA has approved an over-the-counter (OTC)
liquid-filled capsule formulation of aspirin (Vazalore –
PLx Pharma). The manufacturer has been heavily
promoting Vazalore with claims of fast,...
The FDA has approved an over-the-counter (OTC)
liquid-filled capsule formulation of aspirin (Vazalore –
PLx Pharma). The manufacturer has been heavily
promoting Vazalore with claims of fast, predictable
absorption and antiplatelet activity and improved
gastrointestinal safety compared to existing OTC
aspirin formulations.
Drugs for GERD and Peptic Ulcer Disease
The Medical Letter on Drugs and Therapeutics • April 4, 2022; (Issue 1647)
Gastroesophageal reflux disease (GERD) is the most
common GI condition encountered in the outpatient
setting; it affects about 20% of people in the...
Gastroesophageal reflux disease (GERD) is the most
common GI condition encountered in the outpatient
setting; it affects about 20% of people in the US.
Nonopioid Drugs for Pain
The Medical Letter on Drugs and Therapeutics • March 7, 2022; (Issue 1645)
Nonopioid drugs can be used in the treatment of
many nociceptive and neuropathic pain conditions.
For severe pain, especially severe chronic cancer
pain, use of opioids may be necessary....
Nonopioid drugs can be used in the treatment of
many nociceptive and neuropathic pain conditions.
For severe pain, especially severe chronic cancer
pain, use of opioids may be necessary. Noninvasive
nonpharmacologic treatments, including physical
and psychological therapies, have been shown to
improve pain and function in patients with some
common chronic pain conditions and are unlikely
to cause serious harms. A multimodal approach to
analgesic therapy can increase pain control while
reducing opioid use and adverse effects.
Comparison Table: Some Nonopioid Analgesics for Pain (online only)
The Medical Letter on Drugs and Therapeutics • March 7, 2022; (Issue 1645)
...
View the Comparison Table: Some Nonopioid Analgesics for Pain
Minocycline Foam (Zilxi) for Rosacea
The Medical Letter on Drugs and Therapeutics • November 16, 2020; (Issue 1611)
The FDA has approved a 1.5% topical foam formulation
of minocycline (Zilxi – Foamix) for treatment of
inflammatory lesions of rosacea in adults. It is
the only topical minocycline product approved...
The FDA has approved a 1.5% topical foam formulation
of minocycline (Zilxi – Foamix) for treatment of
inflammatory lesions of rosacea in adults. It is
the only topical minocycline product approved for
this indication. The same manufacturer markets
minocycline foam 4% (Amzeeq) for treatment of acne
in patients ≥9 years old.
Drug Interaction: Opioids and Oral P2Y12 Platelet Inhibitors
The Medical Letter on Drugs and Therapeutics • February 25, 2019; (Issue 1566)
The FDA has required manufacturers of the oral P2Y12
platelet inhibitors clopidogrel (Plavix, and generics),
prasugrel (Effient, and generics), and ticagrelor
(Brilinta) to warn in the product labels that...
The FDA has required manufacturers of the oral P2Y12
platelet inhibitors clopidogrel (Plavix, and generics),
prasugrel (Effient, and generics), and ticagrelor
(Brilinta) to warn in the product labels that the
absorption of these drugs may be delayed or reduced
when taken with an opioid agonist.
Drugs for Migraine
The Medical Letter on Drugs and Therapeutics • February 13, 2017; (Issue 1514)
An oral nonopioid analgesic may be sufficient for
treatment of mild to moderate migraine without severe
nausea or vomiting. A triptan is the drug of choice for
treatment of moderate to severe migraine. Use...
An oral nonopioid analgesic may be sufficient for
treatment of mild to moderate migraine without severe
nausea or vomiting. A triptan is the drug of choice for
treatment of moderate to severe migraine. Use of
a triptan early in an attack when pain is still mild to
moderate in intensity improves headache response
and reduces recurrence rates.
Dichlorphenamide (Keveyis) for Periodic Paralysis
The Medical Letter on Drugs and Therapeutics • April 11, 2016; (Issue 1492)
Dichlorphenamide (Keveyis – Taro), an oral carbonic
anhydrase inhibitor, has been approved by the
FDA for treatment of primary hypokalemic and
hyperkalemic periodic paralysis and related...
Dichlorphenamide (Keveyis – Taro), an oral carbonic
anhydrase inhibitor, has been approved by the
FDA for treatment of primary hypokalemic and
hyperkalemic periodic paralysis and related variants.
Dichlorphenamide is the first drug to be approved in
the US for this indication. It was approved as Daranide
in 1958 for treatment of glaucoma, but had not been
marketed since 2002.
Low-Dose Meloxicam (Vivlodex) for Osteoarthritis Pain
The Medical Letter on Drugs and Therapeutics • March 14, 2016; (Issue 1490)
The FDA has approved Vivlodex (Iroko), a low-dose
formulation of the nonsteroidal anti-inflammatory drug
meloxicam (Mobic, and generics), for management of
osteoarthritis pain. According to the manufacturer,...
The FDA has approved Vivlodex (Iroko), a low-dose
formulation of the nonsteroidal anti-inflammatory drug
meloxicam (Mobic, and generics), for management of
osteoarthritis pain. According to the manufacturer, the
new formulation aligns with stronger FDA warnings
about the cardiovascular risks of NSAIDs and the
recommendation to use the lowest possible doses of
these drugs.
Durlaza - A 24-Hour Extended-Release Aspirin
The Medical Letter on Drugs and Therapeutics • January 18, 2016; (Issue 1486)
The FDA has approved Durlaza (New Haven
Pharmaceuticals), a 24-hour extended-release (ER)
aspirin formulation available only by prescription, for
secondary prevention of myocardial infarction (MI)
and...
The FDA has approved Durlaza (New Haven
Pharmaceuticals), a 24-hour extended-release (ER)
aspirin formulation available only by prescription, for
secondary prevention of myocardial infarction (MI)
and stroke.
Edoxaban (Savaysa) - The Fourth New Oral Anticoagulant
The Medical Letter on Drugs and Therapeutics • March 30, 2015; (Issue 1465)
The FDA has approved edoxaban (Savaysa – Daiichi
Sankyo), a once-daily, oral, direct factor Xa inhibitor,
for treatment of venous thromoboembolism (VTE)
and for prevention of stroke and systemic...
The FDA has approved edoxaban (Savaysa – Daiichi
Sankyo), a once-daily, oral, direct factor Xa inhibitor,
for treatment of venous thromoboembolism (VTE)
and for prevention of stroke and systemic embolism
in patients with nonvalvular atrial fibrillation. It is the
fourth new oral anticoagulant to be approved for VTE
and nonvalvular atrial fibrillation.
Drugs for Rheumatoid Arthritis
The Medical Letter on Drugs and Therapeutics • December 22, 2014; (Issue 1458)
For initial treatment of rheumatoid arthritis, most expert clinicians prescribe a disease-modifying antirheumatic drug (DMARD) and add a nonsteroidal anti-inflammatory drug (NSAID) or a corticosteroid to...
For initial treatment of rheumatoid arthritis, most expert clinicians prescribe a disease-modifying antirheumatic drug (DMARD) and add a nonsteroidal anti-inflammatory drug (NSAID) or a corticosteroid to control symptoms. Methotrexate is generally the DMARD of choice...
DMARDs
Disease-modifying antirheumatic drugs (DMARDs) are used early in the treatment of rheumatoid arthritis (RA) to achieve clinical remission, prevent irreversible damage to joints, and minimize toxicity associated with nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. DMARDs generally do not have an immediate analgesic effect, but over time can control symptoms and have been shown to delay and possibly stop progression of the disease. Methotrexate (Rheumatrex, and others) is generally the first DMARD prescribed; it can be used to treat mild, moderate, or severe RA. For mild disease, some clinicians prefer to start with hydroxychloroquine (Plaquenil, and generics) and/or sulfasalazine (Azulfidine, and others).
DMARDs
Disease-modifying antirheumatic drugs (DMARDs) are used early in the treatment of rheumatoid arthritis (RA) to achieve clinical remission, prevent irreversible damage to joints, and minimize toxicity associated with nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. DMARDs generally do not have an immediate analgesic effect, but over time can control symptoms and have been shown to delay and possibly stop progression of the disease. Methotrexate (Rheumatrex, and others) is generally the first DMARD prescribed; it can be used to treat mild, moderate, or severe RA. For mild disease, some clinicians prefer to start with hydroxychloroquine (Plaquenil, and generics) and/or sulfasalazine (Azulfidine, and others).
Antiviral Drugs for Seasonal Influenza 2014-2015
The Medical Letter on Drugs and Therapeutics • December 8, 2014; (Issue 1457)
Antiviral drugs can be used for treatment of influenza
and as an adjunct to influenza vaccination for prophylaxis.
Frequently updated information on influenza
activity and antiviral resistance is available...
Antiviral drugs can be used for treatment of influenza
and as an adjunct to influenza vaccination for prophylaxis.
Frequently updated information on influenza
activity and antiviral resistance is available from the
CDC at www.cdc.gov/flu.
Secondary Prevention of Stroke
The Medical Letter on Drugs and Therapeutics • December 8, 2014; (Issue 1457)
Recent guidelines from the American Heart Association
and American Stroke Association reviewed antithrombotic
therapy options for secondary prevention of
stroke in patients who have had a stroke or...
Recent guidelines from the American Heart Association
and American Stroke Association reviewed antithrombotic
therapy options for secondary prevention of
stroke in patients who have had a stroke or transient
ischemic attack (TIA).
Antithrombotic Drugs
The Medical Letter on Drugs and Therapeutics • October 27, 2014; (Issue 1454)
Antiplatelet drugs are the drugs of choice for
prevention and treatment of arterial thrombosis.
Anticoagulants are the drugs of choice for prevention
and treatment of venous thromboembolism and...
Antiplatelet drugs are the drugs of choice for
prevention and treatment of arterial thrombosis.
Anticoagulants are the drugs of choice for prevention
and treatment of venous thromboembolism and for
prevention of cardioembolic events in patients with
atrial fibrillation.
Vorapaxar (Zontivity) for Prevention of Thrombotic Cardiovascular Events
The Medical Letter on Drugs and Therapeutics • September 15, 2014; (Issue 1451)
The FDA has approved vorapaxar (Zontivity – Merck), an
oral protease-activated receptor-1 (PAR-1) antagonist,
for use with aspirin and/or clopidogrel to reduce the risk
of thrombotic cardiovascular events...
The FDA has approved vorapaxar (Zontivity – Merck), an
oral protease-activated receptor-1 (PAR-1) antagonist,
for use with aspirin and/or clopidogrel to reduce the risk
of thrombotic cardiovascular events in patients with
peripheral arterial disease or a history of myocardial
infarction (MI). It is the first PAR-1 antagonist to be
approved by the FDA.
Low-Dose Aspirin for Prevention of Preeclampsia
The Medical Letter on Drugs and Therapeutics • June 23, 2014; (Issue 1445)
The American College of Obstetricians and Gynecologists
(ACOG) and the US Preventive Services Task
Force (USPSTF) have recommended that women at
risk for preeclampsia take low-dose aspirin daily after
the...
The American College of Obstetricians and Gynecologists
(ACOG) and the US Preventive Services Task
Force (USPSTF) have recommended that women at
risk for preeclampsia take low-dose aspirin daily after
the first trimester.